By Steve Benen Last week, Robert F. Kennedy Jr., a conspiracy theorist whom Republicans put in charge of the Department of Health and Human Services, left little doubt that he would soon announce ...

PARIS, March 31 (Reuters) - France's Ceva Animal Health has raised 5.5 billion euros ($5.95 billion) in equity, boosting its valuation to 9.2 billion euros, as shareholders including the ...

The Formula One legend’s health has been shrouded in secrecy ever since his skiing accident in December 2013 (Picture: Lars Baron/Bongarts/Getty Images) A major update into Michael Schumacher ...

Merck's stock trades at a low valuation as investors worry about Keytruda's looming patent cliff. The company is looking to a new, subcutaneous formulation, which could help sales remain strong ...

After that, Merck has an animal health segment that earned ~$6bn last year, or 9% of revenues, diabetes segment that earned $2.3bn, or 4% of revenues, virology segment, $1.8bn, 2% of revenues ...

Merck has recently achieved a significant milestone with the European Commission's approval of its pneumococcal vaccine CAPVAXIVE®, boosting its portfolio in the vaccines market. Despite this ...

Merck (MRK), known as MSD outside of the United States and Canada, announced that the European Commission, or EC, has approved CAPVAXIVE, or Pneumococcal 21-valent Conjugate Vaccine, for active ...

Apple last year introduced new hearing health features for its AirPods Pro 2 wireless earbuds. Since the features require approval from health regulators, they’ve been rolled out region by region.

Merck (MRK) has signed a licensing agreement for a heart disease drug developed by a Chinese company in a deal worth up to $2 billion, the latest in a series of cross-border deals between Western ...

Merck & Co. is handing over $200 million to China’s Hengrui Pharma for a phase 2-stage lipoprotein(a) (Lp(a)) inhibitor. In return for the ex-China rights to the drug, dubbed HRS-5346, Merck has ...

(Reuters) -Merck has signed a licensing agreement for a heart disease drug with Jiangsu Hengrui Pharmaceuticals worth up to $2 billion, the latest in a series of deals U.S. drugmakers have ...

Merck was one of the pioneers of the cholesterol-lowering statins that launched in the 1980s and 1990s and changed medical practice. But it hasn’t been as successful with cholesterol medicines since ...